IDO2 and neoplasm: The respective resistance mechanism involves the upregulation of indoleamine 2,3-dioxygenase and its interaction with IFNγ, leading to the promotion of tumor immunosuppression through regulatory T-cell-dependent recruitment of myeloid-derived suppressor cells [56,57].